Table 1.
Baseline characteristics of pancreatic cancer patients (n=654)
| Characteristics | Value (%) |
|---|---|
|
| |
| Median age, year (range) | 62 (25–88) |
| Sex | |
| Male | 393 (60.1) |
| Female | 261 (39.9) |
| Body mass index, Kg/m2 (range) | 22.4 (13.0–36.2) |
| Smoking history | 249 (38.1) |
| ECOG performance scale | |
| 0–1 | 450 (68.8) |
| 2 | 174 (26.6) |
| 3 | 30 (4.6) |
| Charlson comorbidity index | |
| 0 | 177 (27.1) |
| 1 | 227 (34.7) |
| 2 | 148 (22.6) |
| 3 | 79 (12.1) |
| 4 | 18 (2.8) |
| 5 | 5 (0.8) |
| Tumor size, cm (range) | 4.5 (1.4–14.0) |
| Primary tumor site | |
| Head | 224 (34.3) |
| Body | 121 (18.5) |
| Tail | 162 (24.8) |
| Overlapping | 147 (22.5) |
| T-classification | |
| 1 | 13 (2) |
| 2 | 82 (12.5) |
| 3 | 188 (28.7) |
| 4 | 371 (56.7) |
| N-classification | |
| 0 | 134 (20.5) |
| 1 | 520 (79.5) |
| Site of metastases | |
| Liver | 438 (67.0) |
| Peritoneum | 239 (36.5) |
| Distant lymph nodes | 150 (22.9) |
| Lung | 98 (15.0) |
| Others | 51 (7.8) |
| Chemotherapy agent | |
| Gemcitabine | 620 (94.8) |
| Cisplatin | 343 (52.4) |
| S-1 | 249 (38.1) |
| 5-FU | 194 (29.7) |
| Irinotecan | 15 (2.3) |
| Erlotinib | 12 (1.8) |
| Nab-paclitaxel | 9 (1.4) |
| Others | 72 (12.8) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.